The BIG CON “Screwing Americans”
The rich and powerful are thrilled... Inflation is GREAT for them. It’s everyone else who’ll get screwed. But according to an ex-Wall Street vet, there’s actually a way for YOU to turn the tables – just make this one move before July 29th.
Click here to see why

SGTX Insider Trading (Sigilon Therapeutics)

Insider Ownership Percentage: 10.90%
Insider Buying (Last 12 Months): $5,400,000.00
Insider Selling (Last 12 Months): $2,000,000.00

Sigilon Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Sigilon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sigilon Therapeutics Share Price & Price History

Current Price: $9.98
Price Change: Price Increase of +0.14 (1.42%)
As of 06/24/2021 04:59 PM ET

This chart shows the closing price history over time for SGTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

Sigilon Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2021Daniel Griffith AndersonDirectorSell200,000$10.00$2,000,000.002,022,222View SEC Filing Icon  
12/8/2020Lilly & Co EliMajor ShareholderBuy300,000$18.00$5,400,000.002,444,443View SEC Filing Icon  
See Full Table
Insider Selling at Sigilon Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Sigilon Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Sigilon Therapeutics (NASDAQ:SGTX)

62.23% of Sigilon Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SGTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sigilon Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/21/2021Citadel Advisors LLC9,147$0.20M0.0%N/A0.029%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC26,084$0.58M0.0%-34.8%0.083%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC104,101$2.33M0.0%-7.4%0.330%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley2,033$45K0.0%-37.1%0.006%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC9,147$0.20M0.0%N/A0.029%Search for SEC Filing on Google Icon
5/18/2021California State Teachers Retirement System11,645$0.26M0.0%N/A0.037%Search for SEC Filing on Google Icon
5/17/2021Royal Bank of Canada1,224$27K0.0%N/A0.004%Search for SEC Filing on Google Icon
5/17/2021Woodline Partners LP34,200$0.76M0.0%+5.4%0.108%Search for SEC Filing on Google Icon
5/17/2021Nuveen Asset Management LLC12,499$0.28M0.0%N/A0.040%Search for SEC Filing on Google Icon
5/17/2021Gilder Gagnon Howe & Co. LLC654,209$14.62M0.1%-1.2%2.075%Search for SEC Filing on Google Icon
5/17/2021Sphera Funds Management LTD.362,239$8.07M0.6%-36.2%1.149%Search for SEC Filing on Google Icon
5/17/2021Goldman Sachs Group Inc.19,649$0.44M0.0%-43.9%0.062%Search for SEC Filing on Google Icon
5/14/2021UBS Asset Management Americas Inc.123,374$2.76M0.0%-1.3%0.391%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp17,281$0.39M0.0%N/A0.055%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp84,394$1.89M0.0%N/A0.268%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC121,940$2.73M0.0%+620.3%0.387%Search for SEC Filing on Google Icon
5/12/2021Ensign Peak Advisors Inc13,500$0.30M0.0%N/A0.043%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.136,366$3.05M0.0%N/A0.433%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG1,536$34K0.0%+197.1%0.005%Search for SEC Filing on Google Icon
5/11/2021New York State Common Retirement Fund2,888$65K0.0%N/A0.009%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.1,284,848$28.72M0.0%+15.6%4.075%Search for SEC Filing on Google Icon
5/7/2021American International Group Inc.4,500$0.10M0.0%N/A0.014%Search for SEC Filing on Google Icon
5/4/2021Victory Capital Management Inc.65,070$1.45M0.0%-4.3%0.206%Search for SEC Filing on Google Icon
4/26/2021Zweig DiMenna Associates LLC103,200$2.31M0.2%+1,564.5%0.328%Search for SEC Filing on Google Icon
4/23/2021Strs Ohio1,900$42K0.0%N/A0.006%Search for SEC Filing on Google Icon
3/10/2021HM Payson & Co.1,028$49K0.0%N/A0.003%Search for SEC Filing on Google Icon
3/2/2021Norges Bank7,500$0.36M0.0%N/A0.025%Search for SEC Filing on Google Icon
3/1/2021UBS Asset Management Americas Inc.125,000$6M0.0%N/A0.414%Search for SEC Filing on Google Icon
2/17/2021Canada Pension Plan Investment Board1,485,185$71.33M0.1%N/A4.919%Search for SEC Filing on Google Icon
2/16/2021Flagship Pioneering Inc.10,370,369$498.09M9.1%N/A34.350%Search for SEC Filing on Google Icon
2/16/2021Squarepoint Ops LLC40,000$1.92M0.0%N/A0.132%Search for SEC Filing on Google Icon
2/16/2021Pura Vida Investments LLC24,722$1.19M0.0%N/A0.082%Search for SEC Filing on Google Icon
2/16/2021Tudor Investment Corp Et Al7,700$0.37M0.0%N/A0.026%Search for SEC Filing on Google Icon
2/16/2021Davidson Kempner Capital Management LP10,000$0.47M0.0%N/A0.033%Search for SEC Filing on Google Icon
2/16/2021Avidity Partners Management LP688,000$33.05M1.1%N/A2.279%Search for SEC Filing on Google Icon
2/16/2021ExodusPoint Capital Management LP16,246$0.78M0.0%N/A0.054%Search for SEC Filing on Google Icon
2/16/2021HarbourVest Partners LLC740,740$35.58M13.9%N/A2.454%Search for SEC Filing on Google Icon
2/12/2021Caas Capital Management LP35,000$1.68M0.0%N/A0.116%Search for SEC Filing on Google Icon
2/12/2021Laurion Capital Management LP10,000$0.48M0.0%N/A0.033%Search for SEC Filing on Google Icon
2/11/2021Citigroup Inc.9,524$0.46M0.0%N/A0.032%Search for SEC Filing on Google Icon
2/11/2021Artal Group S.A.276,000$13.26M0.3%N/A0.914%Search for SEC Filing on Google Icon
2/11/2021Teacher Retirement System of Texas30,000$1.44M0.0%N/A0.099%Search for SEC Filing on Google Icon
2/11/2021Monashee Investment Management LLC561,628$26.98M3.6%N/A1.860%Search for SEC Filing on Google Icon
2/8/2021Philadelphia Trust Co.13,644$0.66M0.1%N/A0.045%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.1,111,888$53.40M0.0%N/A3.683%Search for SEC Filing on Google Icon
2/5/2021SG Americas Securities LLC7,800$0.38M0.0%N/A0.026%Search for SEC Filing on Google Icon
2/4/2021State of Wisconsin Investment Board509,629$24.48M0.1%N/A1.688%Search for SEC Filing on Google Icon
2/1/2021Victory Capital Management Inc.68,000$3.27M0.0%N/A0.225%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More on Sigilon Therapeutics

Today's Range

Now: $9.98
Low: $9.61
High: $10.05

50 Day Range

MA: $12.81
Low: $9.15
High: $18.43

52 Week Range

Now: $9.98
Low: $9.01
High: $54.32

Volume

7,623 shs

Average Volume

138,008 shs

Market Capitalization

$314.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Sigilon Therapeutics?

Sigilon Therapeutics' top insider investors include:
  1. Lilly & Co Eli (Major Shareholder)
  2. Daniel Griffith Anderson (Director)

Who are the major institutional investors of Sigilon Therapeutics?

Sigilon Therapeutics' top institutional shareholders include:
  1. BlackRock Inc. — 4.08%
  2. Gilder Gagnon Howe & Co. LLC — 2.07%
  3. Sphera Funds Management LTD. — 1.15%
  4. JPMorgan Chase & Co. — 0.43%
  5. UBS Asset Management Americas Inc. — 0.39%
  6. Geode Capital Management LLC — 0.39%

Which major investors are selling Sigilon Therapeutics stock?

In the last quarter, SGTX stock was sold by these institutional investors:
  1. Sphera Funds Management LTD.
  2. Goldman Sachs Group Inc.
  3. Squarepoint Ops LLC
  4. Millennium Management LLC
  5. Gilder Gagnon Howe & Co. LLC
  6. Victory Capital Management Inc.
  7. UBS Asset Management Americas Inc.
  8. Morgan Stanley

Which major investors are buying Sigilon Therapeutics stock?

In the previous quarter, SGTX stock was purchased by institutional investors including:
  1. BlackRock Inc.
  2. JPMorgan Chase & Co.
  3. Geode Capital Management LLC
  4. Zweig DiMenna Associates LLC
  5. Northern Trust Corp
  6. Bank of New York Mellon Corp
  7. Ensign Peak Advisors Inc
  8. Nuveen Asset Management LLC
[URGENT] MAJOR BUY ALERT
Since 2016, Teeka Tiwari has trumped the stock market. His investment recommendations have each averaged 281%. That’s 17 times the S&P. And 112 times the average investor, according to JPMorgan!

However, one investment Teeka just uncovered could top them all… It involves former President Biden, billions of dollars, several large banks, and a super-rich family. As well as a MAJOR potential upgrade to our credit cards.

Teeka, who ended up correctly picking the last “investment of the decade,” is declaring this his top pick for the 2020s.
See Teeka's Top Pick...